Patient portrayal
LOCALLY ADVANCED BCC

Evidence that
empowers change

LIBTAYO is the FIRST and ONLY treatment indicated for patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate.1

LIBTAYO was studied in the largest clinical trial for a PD-1 inhibitor in patients with locally advanced BCC following HHI use1

Examine the data
1
Most-Prescribed IO by Oncologists in locally advanced BCC2,3*
  • *Based on IQVIA medical claims data from October 2018 through December 2021. Claims calibrated with actual vials sold.2

LIBTAYO was studied in the largest clinical trial for a PD-1 inhibitor in patients with locally advanced BCC previously treated with an HHI1

explore the data

Review case studies of patients with locally advanced BCC from the clinical trial

See the results

Speak with a LIBTAYO representative or request an in-person visit

Contact a rep
  • BCC=basal cell carcinoma; CSCC=cutaneous squamous cell carcinoma; IO=immunotherapy; PD-1=programmed death receptor-1.
LIBTAYO Surround® logo

Help eligible patients access LIBTAYO and navigate the health insurance process.

Learn About the LIBTAYO Surround Patient Support Program